About IMATIB IMATINIB TABLETS IP
Imatib Imatinib
Imatib contains imatinib and belongs to a class of medications known as protein-tyrosine kinase inhibitor. Imatib is used for the treatment of a type of leukemia (chronic myeloid leukemia or CML), gastrointestinal stromal tumors (GISTs - a type of tumor that grows in the walls of the digestive passages and may spread to other parts of the body). Imatib may also be used to prevent cancer from growing in patients after surgical removal of GIST. Imatib is also used for the treatment of dermatofibrosarcoma protuberans (a tumor that forms under the top layer of skin) when the tumor cannot be removed surgically, has spread to other parts of the body, or has come back after surgery. Imatib is also used to treat mastocytosis (a buildup of large amounts of mast cells in certain parts of the body)..
Available as: 100 mg & 400 mg
Manufactured By: CIPLA
Specifications
- Product Name:Imatib
- Contains:Imatinib
- Strength:100 mg & 400 mg
NOTE :-Imatib is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others sin..............
Powerful Treatment for CML and GISTsIMATIB Imatinib Tablets IP targets and inhibits specific proteins that fuel the growth of abnormal cells in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Its active ingredient, imatinib mesylate, is widely established as an effective therapy, working at the cellular level to significantly reduce disease progression and improve long-term outcomes in adults.
Careful Dosage and AdministrationIMATIB is an oral medication, available in 100 mg and 400 mg strengths. Dosage is strictly individualized based on the patients condition and physicians guidance. Adherence to prescribed instructions is vital to obtain full therapeutic benefit while minimizing the risk of side effects. Never adjust the dose without consulting your healthcare provider.
Safe Storage and HandlingTo maintain potency, IMATIB Tablets should be stored below 25C, away from excessive moisture and direct light. Always keep medication out of reach of children and avoid using the product past its 24-month shelf life. Follow packaging information carefully, including batch and lot numbers for safety monitoring.
FAQs of IMATIB IMATINIB TABLETS IP:
Q: How should I take IMATIB Imatinib Tablets?
A: You should take IMATIB Imatinib Tablets orally with a glass of water, exactly as prescribed by your physician. It is best taken at the same time each day, ideally with food to help minimize stomach upset.
Q: What conditions is IMATIB recommended for?
A: IMATIB is used for adults diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), as determined by your healthcare provider.
Q: When can I expect to notice benefits from taking IMATIB?
A: The time to experience the therapeutic effects varies by individual, but many patients see improvements after several weeks of regular use. Your doctor will monitor your progress through regular check-ups and laboratory tests.
Q: Where should I store IMATIB Tablets at home?
A: Store IMATIB in a cool, dry place below 25C, protected from light and moisture. Ensure the medication remains in its original packaging and is kept out of reach of children.
Q: What are the possible side effects of IMATIB?
A: Common side effects may include nausea, fatigue, muscle cramps, and rash. If you notice severe or persistent side effects, promptly contact your physician for advice.
Q: What process should I follow if I miss a dose of IMATIB?
A: If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose. Do not double up on doses. Always consult your healthcare provider for further instructions.
Q: What is the benefit of using IMATIB for my condition?
A: IMATIB works by specifically inhibiting proteins that contribute to abnormal cell proliferation in CML and GISTs, thus slowing disease progression and improving treatment outcomes as part of a comprehensive cancer care plan.